I spent my 35,000 house deposit on having a baby alone it was the best decision Ive ever made – The Sun

HAVING recently turned 39 and with 35k saved to buy a house, Lisa Green decided to take her life in a different direction.

The single recruitment manager ditched her plans to own a home and spent the money on a baby instead through IVF with a sperm donor.

6

She had always wanted to be a mum, and was happy to do it without a partner. Her dream came true last October when she gave birth to daughter Francesca.

Now, when she sees her baby take her first steps or attempt to say Mummy, she feels like she has hit the jackpot.

Lisa, who is now 40 and lives in Solihull, West Mids, says: I set myself a deadline of having a baby by 40 and I have no regrets.

I had disposable income I was putting aside for a house deposit but I felt the time was ticking more on my fertility than it was on buying a house, and its the best decision I ever made.

6

I love being a single mum. Im very lucky as shes a very well-behaved child.

And Lisa is not alone. According to the Human Fertilisation and Embryology Authority (HFEA) more women than ever are deciding to parent without a partner.

Fertility treatment for single women has almost trebled in a decade. The average age of a woman seeking to start a family without a partner is 39, as clinics report rising numbers of want-to-be-mums struggling to meet someone they want to have kids with.

The number of IVF attempts by women trying to have a baby on their own has gone from 531 in 2008 to 1,352 in 2018.

6

Lisa says: I wasnt bothered that I hadnt met the one yet but I was sure about having children. I never came across anyone that I could picture a future with.

But approaching my forties was the time my sister had her son Charlie and he melted everyones hearts. And being around him definitely made me broody. Thats when I decided to go into motherhood alone and began looking at my options.

Three years ago, Lisa looked into freezing her eggs, but scans and blood tests at BMI The Priory Hospital in Edgbaston, Birmingham showed her fertility was starting to decline so it was not an option.

She says: Although I had lots of eggs, they varied in quality so the chances of falling pregnant were slim. Thats when IVF was mentioned.

6

I was shocked because it wasnt something I had even considered, but I felt it was a case of now or never.

Lisa paid 7,000 for her first round of IVF at BMI The Priory Hospital after choosing a sperm donor online.

She says: I was put in touch with three sperm banks after my IVF consultation with the clinic.

I wanted a white male of medium build with brown hair. It was a surreal experience, and crazy that in less than a year I could be a mum.

6

Although the initial treatment was a success, Lisa miscarried at nine weeks.She says: I was heartbroken. I didnt know why I had miscarried or if it would happen if I tried again.

It was hard but I picked myself up and decided to give it another go.

Lisa spent another 5,500 on a second round of IVF. Two weeks later, she discovered she was expecting again and this time the pregnancy went to plan.

She says: The feeling was out of this world, and putting the nursery together and buying clothes for my baby was so exciting.

I refused to let my fears from my miscarriage creep in and I stayed positive.

I found out I was having a girl at my 20-week scan. Finally getting my wish of becoming a mum before 40 was unbelievable.

When Lisa went into labour she had her mum Tina, 64, and sister Jodie, 34, by her side. Lisa says: I was induced and a day later Francesca was in my arms. She weighed 6lb 11oz and I felt incredibly proud the moment I saw her. There were lots of tears and we were all smitten.

The rest of her savings - 22,500 - went towards her maternity leave. She says: I dont get any additional state benefits. Im self-funded.

6

FAMILY FEUDMy husband bedded my MUM while I almost died in hospital & now theyre married

MEGA BATTLEMeghan showed clear signs of anger in talk at 10k-a-head event, says expert

NEVER AFTERIm a high-class escort and even blokes in happy marriages WILL stray

HEAVY LOADMum-of-11 wants at least 4 more kids & already goes through 600 nappies A WEEK

MEGA DISAPPOINTMENTPrince Philip very disappointed Meghan hasnt supported the monarchy'

NUMBERS UPMum begs for help with sons maths homework & PROFESSOR cant do it - can you?

Lisa is now getting to grips with being a single mum. She says: It still doesnt seem real. Its taken me months to accept shes mine.

I used to worry what other people would say about how Francesca came into the world, but I get only positive comments. Even though I may now never be able to buy a home, I have no regrets.

Theres no time limit on buying a house but there is on having a baby.

COSTS

7,000 first round of IVF.

5,500 second IVF round.

22,500 paid out to help fund her living costs during maternity leave.

TOTAL: 35,000

GOT a story? RING The Sun on 0207 782 4104 or WHATSAPP on 07423720250 or EMAILexclusive@the-sun.co.uk

Read more from the original source:
I spent my 35,000 house deposit on having a baby alone it was the best decision Ive ever made - The Sun

Woman successfully obtains order for use of husband’s frozen sperm without correct forms – Scottish Legal News

Published 28 September 2020

A woman who sought to undergo in vitro fertilisation (IVF) treatment using her late husbands sperm has succeeded in obtaining an order allowing its use for that purpose despite his not signing the relevant forms.

The petitioner, SB, wished to pursue IVF as it was the most likely method of success for conception in her circumstance. It was discovered the day before her husbands death that the consent forms completed by her husband only applied to intra uterine insemination (IUI).

The petition was heard by the Lord Justice Clerk, Lady Dorrian, sitting with Lord Glennie and Lord Woolman.

Wrong forms

The will of the petitioners late husband, JB, contained a clause relating to the storage and use of his sperm following his death. JB was advised by his doctor at the onset of the illness from which he died to store his sperm in case he wished to have children in the future. JB died in 2019, with the sperm being collected at a fertility centre approximately 10 years before.

At the time that JB stored his sperm, he did not have a partner. As a result, he was not given the relevant consent form for IVF. JB and the petitioner commenced fertility treatment during the final bout of his illness. Due to the fertility clinic not appreciating that time was of the essence, JB was receiving palliative care at the time an appointment was offered.

At this late stage it became apparent that the forms originally signed by JB were only those appropriate for men without a partner, and JB was unconscious and therefore unable to sign further forms. Affidavits given by the petitioner and a consultant indicated that IVF was the method of treatment most likely to succeed in the couples circumstances.

During JBs final illness, he had his solicitor insert a clause into his will directing that his executors ensure that his sperm be made available to the petitioner for as long as she may wish. It was submitted for the petitioner that the deceaseds will provided the consent required by the Human Fertilisation and Embryology Act 1990.

Answers to the petition were lodged by the Human Fertilisation and Embryology Authority, NHS Grampian, and the Advocate General for Scotland. Opposition was maintained only on the basis that the result would subvert the statutory scheme, and the granting of orders was not opposed if the court was satisfied that the will constituted effective consent.

Expression of wishes

The opinion of the court was delivered by Lady Dorrian. After deciding that the petition was competent, she laid out the requirements for effective consent, saying that they were: (a) It must be in writing; (b) It must be signed by the deceased; (c) It must specify the purpose of use, and be clear that it encompasses consent to the creation of any embryo in vitro; (d) The individual must have been given a suitable opportunity to receive proper counselling about the implications of taking the proposed steps, and have been provided with such relevant information as is proper; and of the consequences in respect of the possibility of variation or withdrawal of consent; and (e) It must not have been withdrawn.

Applying these criteria to the present case, she said: The terms of the deceaseds will constitute sufficient consent to meet these requirements. It is in writing, it is signed and it has not been withdrawn. The remaining two conditions for effective consent relate to the opportunity for counselling and whether the terms of the clause are sufficiently clear to provide consent for the specific form of treatment that is involved in IVF.

On the construction of the deceaseds will, she said: We regard the following features as important. First, it is a testamentary document in which JB was not only making disposition of his estate but, by this clause, expressing his wish for the future use of his stored gametes. Second, he and his wife had sought and been referred for treatment to enable them to have a child. Third, although it is expressed as a direction to his executors, in reality it is an expression of his wishes.

She continued: For present purposes, we are not concerned with whether the clause could be given testamentary effect. The only question is whether it can be construed as granting the necessary consent. In our view there is no doubt that it can. It is the sort of provision that would only sensibly be made by a man contemplating his death in the near future, and seeking to make his wishes clear.

On the length of the storage period, she said: Where it is desired to store gametes for a period in excess of ten years for the provision of treatment services there must be written consent of the donor and a medical opinion to the effect that that person was, or may have been likely to become, prematurely infertile. The clause in the deceaseds will, specifying that the material be available to the petitioner for as long as possible, together with the opinion of the treating oncologist as to the deceaseds state of fertility, clearly meet these requirements.

For these reasons, the court granted orders that JB gave effective consent for the storage and use of his gametes for the purpose of IVF, subject to the statutory storage period.

Scottish Legal News Ltd 2020

Here is the original post:
Woman successfully obtains order for use of husband's frozen sperm without correct forms - Scottish Legal News

Tragic Genetic Heritage: The Ancient Neanderthal Hand in Severe COVID-19 – SciTechDaily

By Okinawa Institute of Science and Technology Graduate UniversitySeptember 30, 2020

Since first appearing in late 2019, the novel virus, SARS-CoV-2, has had a range of impacts on those it infects. Some people become severely ill with COVID-19, the disease caused by the virus, and require hospitalization, whereas others have mild symptoms or are even asymptomatic.

There are several factors that influence a persons susceptibility to having a severe reaction, such as their age and the existence of other medical conditions. But ones genetics also plays a role, and, over the last few months, research by the COVID-19 Host Genetics Initiative has shown that genetic variants in one region on chromosome 3 impose a larger risk that their carriers will develop a severe form of the disease.

Now, a new study, published in Nature, has revealed that this genetic region is almost identical to that of a 50,000-year old Neanderthal from southern Europe. Further analysis has shown that, through interbreeding, the variants came over to the ancestors of modern humans about 60,000 years ago.

It is striking that the genetic heritage from Neanderthals has such tragic consequences during the current pandemic, said Professor Svante Pbo, who leads the Human Evolutionary Genomics Unit at the Okinawa Institute of Science and Technology Graduate University (OIST).

These genetic variants are almost completely absent in Africa and occur in the highest frequency in Bangladesh. Credit: Professor Svante Pbo and Professor Hugo Zeberg. This figure appeared in the publication in Nature.

Chromosomes are tiny structures that are found in the nucleus of cells and carry an organisms genetic material. They come in pairs with one chromosome in each pair inherited from each parent. Humans have 23 of these pairs. Thus, 46 chromosomes carry the entirety of our DNA millions upon millions of base pairs. And although the vast majority are the same between people, mutations do occur, and variations persist, at the DNA level.

The research by the COVID-19 Host Genetics Initiative looked at over 3,000 people including both people who were hospitalized with severe COVID-19 and people who were infected by the virus but werent hospitalized. It identified a region on chromosome 3 that influences whether a person infected with the virus will become severely ill and needs to be hospitalized.

The identified genetic region is very long, spanning 49.4 thousand base pairs, and the variants that impose a higher risk to severe COVID-19 are strongly linked if a person has one of the variants then theyre very likely to have all thirteen of them. Variants like these have previously been found to come from Neanderthals or Denisovans so Professor Pbo, in collaboration with Professor Hugo Zeberg, first author of the paper and a researcher at the Max Planck Institute for Evolutionary Anthropology and Karolinska Institutet, decided to investigate whether this was the case.

They found that a Neanderthal from southern Europe carried an almost identical genetic region whereas two Neanderthals from southern Siberia and a Denisovan did not.

Next, they questioned whether the variants had come over from Neanderthals or had been inherited by both Neanderthals and present-day people through a common ancestor.

If the variants had come from interbreeding between the two groups of people, then this would have occurred as recently as 50,000 years ago. Whereas, if the variants had come from the last common ancestor, they would have been around in modern humans for about 550,000 years. But random genetic mutations, and recombination between chromosomes, would have also occurred during this time and because the variants between the Neanderthal from southern Europe and present-day people are so similar over such a long stretch of DNA, the researchers showed that it was much more likely that they came from interbreeding.

Professor Pbo and Professor Zeberg concluded that Neanderthals related to the one from southern Europe contributed this DNA region to present-day people around 60,000 years ago when the two groups met.

Professor Zeberg explained that those who carry these Neanderthal variants have up to three times the risk of requiring mechanical ventilation. Obviously, factors such as your age and other diseases you may have also affect how severely you are affected by the virus. But among genetic factors, this is the strongest one.

The researchers also found that there are major differences in how common these variants are in different parts of the world. In South Asia about 50% of the population carry them. However, in East Asia theyre almost absent.

It is not yet known why the Neanderthal gene region is associated with increased risk of becoming severely ill. This is something that we and others are now investigating as quickly as possible, said Professor Pbo.

Reference: The major genetic risk factor for severe COVID-19 is inherited from Neanderthals by Hugo Zeberg and Svante Pbo, 30 September 2020, Nature.DOI: 10.1038/s41586-020-2818-3

See the original post here:
Tragic Genetic Heritage: The Ancient Neanderthal Hand in Severe COVID-19 - SciTechDaily

The aquatic chicken: tilapia genetics and their parallels with poultry – The Fish Site

When considering ongoing genetic improvement efforts in tilapia culture, comparisons with the development of the modern chicken industry often present themselves.

C Greg Lutz

Some 150 years ago, global poultry production looked quite a bit like tilapia production did in 1970. Chicken production was seasonal in many parts of the world because of climate and nutritional constraints, and it was a very fragmented industry, focusing mostly on local or regional markets. As a result, there were hundreds of localised chicken breeds and the culture of different birds in different localities was the norm.

Throughout the world the past century saw a shift from this fragmented industry, based on subsistence- and small-scale production, to vertically integrated facilities and specialised hatchery businesses with a focus on genetic improvement. This trend continues today, as industrial production expands in less developed nations.

The original focus of chicken breeders involved both egg and meat production in the same birds, but this shifted to separate breeding goals after World War I. At that point, production of meaty birds, known as broilers, became distinctly differentiated from that of the layers that supplied eggs. When broilers were first commercialised, mass selection was the approach used to improve production and meat yield. This resulted in moderate progress, because at the time most breeding flocks exhibited heritabilities ranging from 0.2 to 0.4.

In the tilapia industry the importance of meat yield is finally gaining more recognition as an important breeding goal. Heritabilities for fillet yield, ranging from 0.2 to 0.38 from 130 to 210 days of age, were reported in a population of Nile tilapia in Brazil (Turra et al. 2012) and a heritability of 0.25 was reported from Malaysia (Nguyen et al. 2010), but Gjerde et al. (2012) reported a much lower value of 0.06 for a line from Nicaragua. More recently, Yoshida et al. (2019) reported a modest increase in heritability estimates when using genomic information on a population in Costa Rica.

In chickens we see a negative correlation between growth and fecundity, so reproductive capacity is important in female lines, even when meat production is the ultimate goal. In tilapia improvement programmes, growth is also usually the breeding goal, but spawning success and frequency are critical considerations in commercial hatcheries. Heritability of spawning success was reported as 0.14 to 0.22 for a population of Nile tilapia in Vietnam, depending on the statistical model and spawning period.

In the years following World War II, chicken breeders began to cross distinct lines to produce broiler chicks. One reason was to maintain female lines that exhibited good egg production while crossing these with male lines that might be less productive as a result of intense selection for growth. This same practice occurs in many tilapia hatcheries around the world. Modern broiler production has evolved into a five-year process where four distinct lines are crossed to ultimately produce chicks. Crossing distinct lines is still not a common practice in tilapia production, but for a period of time hybrids were quite popular in China and also in Israel. At one time the breeding programme of a large tilapia operation in Honduras was based on a double crossing design similar to those used in the chicken industry.

Disease resistance has been an important component of chicken breeding programmes for many decades. In tilapia, a similar emphasis is taking hold. The recent emergence of tilapia lake virus (TiLV) has caused concern across the globe, but new research suggests breeding programmes to reduce or eliminate this threat may be possible. Using data from 124 O. niloticus families in Malaysia, researchers estimated heritabilities for TiLV resistance ranging from 0.48 to 0.56, with family survival ranging from 0 percent to 100 percent (Barria et al. 2020).

Some of the more long-standing tilapia pathogens are still causing major problems. Many tilapia hatcheries struggle with Flavobacterium columnare, the causative agent for columnaris disease. Selective breeding has been shown as a means to improve resistance to columnaris in tilapia, and this is important in tropical regions, where vaccines are not available and antibiotic resistance is on the rise. Researchers working with the Chitralada 4 strain in Thailand reported heritability estimates for columnaris resistance ranging from 0.14 to 0.30, based on different statistical models, with family survival rates ranging from 8 percent to 70 percent (Wonmongkol et al. 2017). Genetic influence over resistance to Streptococcus iniae and S. agalactiae have also been demonstrated, with heritabilities of 0.52 and 0.38, respectively, but resistance to one pathogen does not appear to confer resistance to the other (Shoemaker et al. 2016). Dr Carlos Lozano, with Spring Genetics, stated that selection for disease resistance is among the tilapia industrys top priorities for genetic improvement, adding In particular diseases like S. Iniae, S. agalactiae, Francisella,TiLV and columnaris.

C Greg Lutz

By the 1960s, chicken improvement programmes were emphasising the importance of feed conversion efficiency. This trait is quite difficult to measure in fish, but recent study demonstrated significant genetic control over it in Nile tilapia, with an estimated heritability of 0.32 (de Verdal et al. 2018). One genetic correlation with feed efficiency that was significant was weight loss at fasting (0.80), which would allow indirect selection for individuals with superior FCR while avoiding the complex task of measuring individual feed intake.

As quantitative genetic tools and selection programmes became more sophisticated, the chicken breeding sector began to consolidate, and most breeding programmes adopted selection indices that included more than 40 distinct physiological traits relating to feed efficiency, disease resistance, skeletal structure and behaviour. By the late 2000s only three major breeding companies dominated the market: Cobb-Vantress, Aviagen and Group Grimaud (a multi-species company based in Europe that also has interests in aquaculture species).

Over time, genetic improvement tools for chickens have evolved from mass selection, to index selection, to the use of BLUP estimates, to marker-assisted selection and now genomic selection is becoming the norm. When I asked Dr Lozano to cite some of the most important developments in tilapia improvement in recent years, he indicated: The recent development of SNP chips for tilapia has enabled the inclusion of marker assisted (MAS) and genomic selection in tilapia breeding programmes (eg Spring Genetics and GenoMar). This is especially important for disease resistance, where generally family selection was used and candidates were selected based on the performance of their siblings. With genomic selection we can select candidates based on their individual genetic merit. Gene-editing technologies have also recently been applied by AquaBounty and approved for Nile tilapia in Argentina.

Since there are so few genetic nuclei, modern industrial chicken lines must be adaptable to conditions found around the globe. Unlike a century ago, when any number of local chicken breeds could be found around the world, the birds being produced by these large corporations must incorporate adaptability to a variety of grow-out conditions and diets. This potential conflict between centralised breeding operations and a multitude of grow-out environments may eventually become an issue for tilapia producers as improved lines are disseminated across the globe. When asked about this, Dr Lozano commented: I envision the dissemination of superior genetics mostly to industrial scale producers. For small scale producers the low profit margin may restrict their accessibility to high quality fry.

Modern chickens are largely descended from the red jungle fowl, but at least one other related species appears to have contributed to the birds we raise today. Many lines of O. niloticus also include genetic contributions from other species. However, while the genome of the modern chicken has been relatively stable over the past century, this milestone is yet to be attained in tilapia. Not all tilapia are created equal. Researchers in Thailand used microsatellite genetic markers to examine changes in four lines of Nile tilapia (Oreochromis niloticus) derived from the genetically improved farmed tilapia (GIFT) strain, and in two lines derived from a local Chitralada strain. Three of the four GIFT-derived populations remained relatively pure, with no decline in genetic variation. However, one of the GIFT-derived populations showed high levels of introgression from the Chitralada strain, and the Chitralada-derived populations exhibited introgression from GIFT lines. Introgression from O. mossambicus was also observed in one of the Chitralada-derived lines and from O. aureus in one of the GIFT-derived lines (Sukmanomon et al. 2011).

C Espejo Genipez Viterbo

The situation regarding some semblance of genomic standardisation becomes even more complicated with red tilapia. In many parts of the world, consumers demand red-coloured fish. Although red colouration has been established in O. niloticus (the red Stirling line) through the isolation and propagation of a single red mutant (McAndrew et al. 1988, Hussain 1994), most strains of red tilapia include genetic contributions from several distinct species including slower-growing O. mossambicus and O. urolepis hornorum (Desprez et al. 2006). In recent years efforts to develop robust commercial lines of red O niloticus have advanced through backcrossing red Stirling fish with fast-growing strains such as GIFT and Chitralada (Lago et al. 2017). In Colombia, my colleague Carlos Espejo has adapted a similar strategy, crossing local red lines of multi-species ancestry with Chitralada-based wild-type fish.

Just as most unimproved varieties of chickens would not perform very well in commercial chicken houses, most industrial birds would not survive long in the farmyards of subsistence farmers around the globe. Many local varieties of chicken persist around the world, and leaving aside all the introgression and hybridisation that has occurred over the past century, even within pure O. niloticus a similar array of variation can be found in terms of local and regional strains. Africa as a whole is a region of concern in terms of conserving genetic resources scattered among hundreds of local stocks of Nile tilapia. In the case of chickens, many historically recognised European, Asian and North American breeds were already reported as extinct by the FAO in 2007, having been replaced by modern varieties. Many more breeds were listed as at risk at that time. However, in regions where subsistence farming still plays a significant role in food production, indigenous chicken breeds persist, due to their accumulated adaptation to local conditions. Hopefully the same will hold true for tilapia.

References available from the author.

His career has included experience with numerous aquatic species in a number of countries. Dr Lutz is also the author of the book Practical Genetics for Aquaculture.

The rest is here:
The aquatic chicken: tilapia genetics and their parallels with poultry - The Fish Site

The genetics of poop and how it can help our health and threaten our privacy – Genetic Literacy Project

Everyone pees and poops. We excrete metabolites, vitamins, microbes, and even our own cells. This information makes its way into a wastewater treatment plant, creating a community-wide stool or urine sample. Wastewater epidemiologists can leverage our waste to detect disease outbreaks, drug use, and more. So what exactly can we detect and how is this information protected?

However, using sewage to monitor a communitys lifestyle and general health may seem, to many, more intrusive than monitoring disease outbreaks. At the University of Queensland, scientists were able topredict socioeconomic information using wastewater.This group of researchers used biomarkers from wastewater to predict 37 characteristics from the Australian Census including median age, education, and employment.

The Sewage Analysis CORe group Europe put together a set ofguidelines addressing ethical research practices for sewage epidemiologynoting that theres historically been little oversight by research ethics committees as wastewater data is not collected on individuals. Some of their mitigation strategies include aggregating samples from multiple sites, and removing names and locations of sampling sites.

Wastewater based epidemiology has the potential to gauge the health of our cities, but before reaping the benefits, scientists should also weigh and address the concerns. Sewer data used for research to understand population trends is much different from using the data for policy or punishment.

Read the original post

See the article here:
The genetics of poop and how it can help our health and threaten our privacy - Genetic Literacy Project

Pac-12 adds to RT-PCR COVID-19 testing capabilities with Fulgent Genetics partnership – Pac-12.com

New RT-PCR testing partnership to supplement existing testing capabilities across Pac-12 athletics departments

SAN FRANCISCO The Pac-12 today announced a conference-wide surveillance testing partnership for SARS-CoV-2 (COVID-19) with Fulgent Genetics (NASDAQ: FLGT) as part of its on-going student-athlete health & well-being initiatives (SAHWBI) efforts. Under the partnership, Fulgent Genetics will provide RT-PCR (reverse transcription polymerase chain reaction) testing capabilities to supplement existing PCR and antigen testing capabilities across each Pac-12 athletics department. The partnership follows and is in addition to the Pac-12s recently announced partnership with Quidel Corporation for daily rapid-results testing capabilities (point-of-care).

We are excited to be partnering with a leading testing company in Fulgent to provide our athletic departments with the very best capabilities to protect the health and well-being of our student-athletes, said Pac-12 Commissioner Larry Scott. On the heels of our agreement with Quidel to provide rapid-results testing, todays announcement represents another important step in providing a safe and healthy environment for a return to competition for our student-athletes.

Dr. Doug Aukerman, senior associate athletics director for Oregon State and chair of the Pac-12 SAHWBI added: Providing additional resources at the level of what Fulgent Genetics offers is a tremendous addition for our athletics departments and staff as we continue to strive for the most secure and safe environment for our student-athletes return to play.

Routine, rapid testing is playing a key role in limiting the spread of COVID-19 and is helping to keep players, coaches and staff safe as they look to return to competition. The Pac-12 has implemented several protocols in this area, and the RT-PCR testing provided by Fulgent Genetics is an important part of this process, said Brandon Perthuis, Chief Commercial Officer of Fulgent Genetics. RT-PCR is regarded as the gold standard in COVID-19 testing, providing the highest level of sensitivity and specificity. At Fulgent, we have built technology platforms around our test to make it scalable for the Pac-12, which allows us to deliver results within 24 hours of receipt of the sample for testing. We are excited to partner with the Pac-12 and look forward to helping keep their athletic programs running safely.

Each Pac-12 institution currently has RT-PCR testing practices and protocols in place for their athletics departments. With the new partnership, Fulgent Genetics will be able to serve as a supplemental resource for each athletics department. The RT-PCR testing program from Fulgent Genetics will be driven by the new Fulgent Enterprise COVID-19 Screening Platform, which provides an end-to-end solution for routine and repeat testing, including onsite testing for student-athletes and staff, 24-hour results and mobile delivery and interface.

For more information about COVID-19 testing options from Fulgent Genetics please visit fulgentgenetics.com/COVID19.

About the Pac-12 Student-Athlete Health and Well-Being Initiative

Created in 2013, the Pac-12 Student-Athlete Health and Well-Being Initiative (SAHWBI) is a collective effort between the Pac-12 and all 12 member universities to find ways to reduce injuries, share current best practices and latest studies and conduct research to uncover new ways to keep student-athletes as safe as possible. For more information, go to Pac-12.com/health.

Aboutthe Pac-12 Conference

The Conference has a tradition as the Conference of Champions, leading the nation in NCAA Championships in 54 of the last 60 years, with 529NCAA team titles overall. The Conference comprises 12 leading U.S. universities - the University of Arizona, Arizona State University, the University of California,Berkeley, the University of California at Los Angeles (UCLA), the University of Colorado, the University of Oregon, Oregon State University, Stanford University, the University of Southern California, the University of Utah, the University of Washington and Washington State University. For more information on the Conferences programs, member institutions, and Commissioner Larry Scott, go toPac-12.com/conference.

About Fulgent Genetics

Fulgent Genetics is a growing technology company with an initial focus on offering comprehensive genetic testing to provide physicians with clinically actionable diagnostic information they can use to improve the quality of patient care. The company has developed a proprietary technology platform that integrates sophisticated data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools and integrated laboratory processes. This platform allows the company to offer a broad and flexible test menu and continually expand and improve its proprietary genetic reference library, while maintaining accessible pricing, high accuracy and competitive turnaround times. The company believes its current test menu, which includes approximately 18,000 single-gene tests and more than 850 pre-established, multi-gene, disease-specific panels, offers more genes for testing than its competitors in todays market, which enables it to provide expansive options for test customization and clinically actionable results.

Follow this link:
Pac-12 adds to RT-PCR COVID-19 testing capabilities with Fulgent Genetics partnership - Pac-12.com

Research in Manitoba and Saskatchewan looking at genetics to help fight COVID-19 pandemic – CTV News Winnipeg

WINNIPEG -- New research out of the Prairies will be producing genomic data to help inform public health decisions during the COVID-19 pandemic.

On Sept. 29, Genome Prairie announced the launch of its Canadian COVID-19 Genomics Network (CanCOGeN) research projects, which will take place in Manitoba and Saskatchewan.

CanCOGeN, which was first announced in April 2020, is a $40-million network involving federal, provincial, and regional public health authorities, as well as academia and industry. The goal of the network is to coordinate and fund coronavirus and host genome sequencing efforts and to share and analyze the data.

Genome Prairie is proud to launch today, our two regional CanCOGeN projects: one in the Cadham Provincial Lab in Winnipeg and one in the Roy Romanow Provincial Lab in Regina, said Gerry Brown, interim president and CEO of Genome Prairie.

Both these invaluable projects have the capability to have a rapid and material impact on evolving COVID-related challenges.

The two projects are called the Virus Genome Sequencing Project (VirusSeq) and the Host

Genome Sequencing Project (HostSeq).

VirusSeq will focus on large-scale whole-genome sequencing, identifying genetic mutations and variations. This data will help with COVID-19 surveillance, contact tracing, tracking, dispersal, and management.

HostSeq involves whole genome sequencing of infected people in order to understand the clinical responses to infection, which range from mild discomfort to serious respiratory complications.

It is with no doubt that as we continue to fight against COVID-19, Genome Prairies expertise and leadership is needed to help us resolve and better understand the many COVID-19-related challenges we are faced with today, said MP Terry Duguid.

Duguid added these projects will gather scientific data to help better protect Canadians from this virus.

Genome Prairie is also working on its COV3R project, which is looking at the issue of detecting co-infections and providing new tools for public health.

See the article here:
Research in Manitoba and Saskatchewan looking at genetics to help fight COVID-19 pandemic - CTV News Winnipeg

Blocking the self-destruction process of enzymes can mitigate age-related diseases – News-Medical.Net

Reviewed by Emily Henderson, B.Sc.Sep 30 2020

Stopping the cannibalistic behavior of a well-studied enzyme could be the key to new drugs to fight age-related diseases, according to a new study published online in Nature Cell Biology.

For the first time, researchers in the Perelman School of Medicrestore ine at the University of Pennsylvania show how the self-eating cellular process known as autophagy is causing the SIRT1 enzyme, long known to play a role in longevity, to degrade over time in cells and tissue in mice.

Identifying an enzymatic target is an important step that may lead to new or modified existing therapeutics.

"Blocking this pathway could be another potential approach to restore the level of SIRT1 in patients to help treat or prevent age-related organ and immune system decline," said first author Lu Wang, PhD, a postdoctoral researcher in the lab of Shelly Berger, PhD, a professor of Cell and Developmental Biology in the Perelman School of Medicine and a professor of Biology in the School of Arts and Sciences at Penn. Berger also serves as senior author on the paper.

The findings may be of most interest to the immune aging field, as autophagy's role in SIRT1 in immune cells is a concept that hasn't been shown before," Wang added. "Exploiting this mechanism presents us with a new possibility of restoring immune function."

Lu Wang, PhD, Study First Author and Postdoctoral Researcher,

Cells are like leaky faucets, dripping away levels of proteins and enzymes, such as SIRT1, as the body ages, which can lead to chronic diseases, organ decline, and weaker immune responses to infections.

New ways to stop these leaks and replenish SIRT1 have been demonstrated, including by cardiovascular researchers at Penn Medicine, but this is the first study to show autophagy's role in that degradation during senescence--a natural process in which cells stop creating new cells--and aging.

SIRT1 is crucial for cell metabolism and immune responses, researchers have known, and has been shown to extend lifespan when overexpressed.

To determine the mechanism of SIRT1 loss during senescence, the researchers first ruled out it was driven by mRNA synthesis and stability, important factors in the control of gene expression, using RNA sequencing techniques on mouse cells.

Instead, through further experiments, they found that "knocking out" the autophagic protein Atg7 in senescent cells left SIRT1 levels in place, indicating the autophagic pathway, and not proteasomes--the other recycling factory of the body--played a role in the loss of the enzyme. Immunofluorescence staining also showed that another autophagy protein, LC3, drives the loss of SIRT1 in senescent cells and tissue.

Treating mice with various drugs further supported autophagy's role. A proteasome inhibitor--which blocks the breakdown of proteins in the cell--failed to restore SIRT1 protein in senescent cells and tissue, while treatment with Lys05, an autophagy inhibitor, rescued the loss of SIRTI, supporting that the enzyme is degraded through lysosomes. Lysosomes are the "stomach" of cells that help break down larger waste materials.

To determine autophagy's role in SIRT1 in immune cells, the researchers treated human donor CD8 T cells with low-dose Lys05 and a proteasome inhibitor, and found that only Lys05 increased SIRT1 levels.

The results, the authors said, indicate that SIRT1 is degraded at least in part through the autophagy-lysosome pathway during T cell aging in humans--a mechanism that could inform the reprograming of aged immune cells.

Next, the researchers will further explore the LC3 and SIRT1 interaction in preclinical studies and better characterize the signaling pathway to block it.

"Stabilizing SIRT1 protein level by interrupting this interaction could be a new direction for the design of anti-aging compounds," the authors said.

Source:

Journal reference:

Xu, C., et al. (2020) SIRT1 is downregulated by autophagy in senescence and ageing. Nature Cell Biology. doi.org/10.1038/s41556-020-00579-5.

Read the original post:
Blocking the self-destruction process of enzymes can mitigate age-related diseases - News-Medical.Net

Researchers discover specific cellular pathway involved in lung tissue regeneration – News-Medical.net

Reviewed by Emily Henderson, B.Sc.Sep 28 2020

Researchers at Children's Hospital of Philadelphia (CHOP) and the Perelman School of Medicine at the University of Pennsylvania have identified a cellular pathway that can be targeted with a naturally occurring drug to stimulate lung tissue regeneration, which is necessary for recovery from multiple lung injuries. The findings, which were published today in Nature Cell Biology, could lead to better therapies for patients with lung disease, including acute respiratory distress syndrome (ARDS) due to COVID-19.

Using cutting-edge technology, including genome-wide and single-cell analyses, we have identified a specific cellular pathway involved in lung tissue regeneration and found a drug that enhances this process. These findings provide identification of precision targets and thus allow for rational development of therapeutic interventions for lung disease caused by COVID-19 and other illnesses."

G. Scott Worthen, MD, senior author, physician-scientist in CHOP's Division of Neonatology and member of the Penn-CHOP Lung Biology Institute

Conditions like pneumonia, influenza and ARDS - one of the known complications of COVID-19 - can damage the lining of the air sacs in the lungs, known as the alveolar epithelium, which prevents oxygen from passing from the lungs to the bloodstream and can lead to death. Patients with COVID-19 who develop ARDS become critically ill, and to date, no drugs have been developed specifically to treat ARDS in COVID-19 patients. Understanding which genetic targets and pathways are involved in regenerating epithelial tissue is critical in developing effective therapies for ARDS and similar conditions.

Previous research has shown that type II alveolar pneumocytes (AT2) are important cells involved in lung repair, both through self-renewal and transdifferentiation into type I alveolar pneumocytes (AT1), which facilitate gas exchange between the lung air sacs and nearby capillaries. Yet prior to this study, it was unknown what changes in gene accessibility occurred in AT2 cells following disease-related injury to promote repair and how regenerating AT2 cells influence interactions with nearby mesenchymal cells, which are also important in tissue repair.

Using genome-wide analyses, the research team assessed changes in AT2 after lung injury, which opens up the chromosomes within the cells and makes specific genes available to the machinery of the cell. The researchers then used single-cell analysis of AT2 cells and mesenchymal cells to better understand how the two cell types interact during injury and what cell signaling pathways are involved. The two approaches converged on a single pathway, in which a transcription factor known as STAT3 increased the expression of brain-derived neurotrophic factor (BDNF), which in turn increased lung tissue regeneration.

In further analyzing this pathway, the researchers identified a naturally-occurring compound known as 7,8-Dihydroflavone (7,8-DHF), which targeted a receptor in the pathway, stimulating and accelerating lung tissue repair in multiple mouse models of lung injury.

"We believe these findings could lead to the development of a new therapeutic that could help patients recovering from COVID-19 and similar diseases," said the study's first author, Andrew J. Paris, MD, Instructor of Medicine and a pulmonary specialist in the Perelman School of Medicine at the University of Pennsylvania. "Based on the results of this study, we think 7,8-DHF is an excellent candidate for entering clinical trials for patients with lung diseases."

Source:

Journal reference:

Paris, A.J., et al. (2020) STAT3BDNFTrkB signalling promotes alveolar epithelial regeneration after lung injury. Nature Cell Biology. doi.org/10.1038/s41556-020-0569-x.

Read more:
Researchers discover specific cellular pathway involved in lung tissue regeneration - News-Medical.net

Dewpoint Therapeutics raises $77 million to go after undruggable diseases – BetaBoston

Dewpoint Therapeutics announced Tuesday that it has raised $77 million in its second round of venture funding, which will help the company continue to target undruggable diseases through an emerging field in cell biology.

The Boston-based biotech works on organelles inside cells called biomolecular condensates, which it believes can be harnessed to treat diseases including cancer and rare genetic disorders. Condensates are membrane-less droplets that help cells perform vital functions.

The funding round was led by Chicago-based ARCH Venture Partners, bringing Dewpoints total venture financing to $147 million. The deal attracted new investors Maverick Ventures and Bellco Capital, and previous investors Leaps by Bayer, EcoR1 Capital, Polaris Partners, Samsara BioCapital, and Innovation Endeavors also participated in the round.

Todays announcement underscores the interest in biomolecular condensates among investors with a track record of backing groundbreaking science," Amir Nashat, managing partner of Polaris Partners and interim chief executive of Dewpoint, said in a news release.

Since its founding in 2018, Dewpoint has signed deals with two pharmaceutical giants. In July, Dewpoint announced a collaboration with Merck & Co. to work on the treatment of HIV, and in November, Dewpoint announced it would work with German pharmaceutical company Bayer to develop new treatments for cardiovascular and gynecological diseases.

Dewpoint also announced Tuesday that Giuseppe Ciaramella, the president and chief scientific officer of Beam Therapeutics, would join its board of directors. Prior to Beam, Ciaramella worked at Moderna in Cambridge, first as head of immunology and biotherapeutics and then as chief scientific officer of its infectious diseases division.

Anissa Gardizy can be reached at anissa.gardizy@globe.com. Follow her on Twitter @anissagardizy8.

Read more from the original source:
Dewpoint Therapeutics raises $77 million to go after undruggable diseases - BetaBoston